GS
UTHR icon

George Soros’s United Therapeutics UTHR Stock Holding History

George Soros’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,054
Closed -$242K – 229
2024
Q1 		$242K Buy
+1,054
New +$238K ﹤0.01% 193
2016
Q1 		– Sell
-4,400
Closed -$689K – 309
2015
Q4 		$689K Buy
+4,400
New +$641K 0.01% 174

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

George Soros's UTHR Position: Q2 2024 in Review

George Soros sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 1,054 shares — an estimated $242K sold.

George Soros first reported a position in UTHR in Q4 2015 and held it in 2 quarters. The position peaked at $689K in Q4 2015. 568 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • George Soros reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • George Soros sold 1,054 United Therapeutics shares in Q2 2024, an estimated $242K.
  • George Soros first reported a position in United Therapeutics in Q4 2015 and held it in 2 quarters.
  • George Soros's United Therapeutics position peaked at $689K in Q4 2015.
  • 568 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Soros Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.